TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 46
4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50
5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51
6 MARKET OVERVIEW 54
6.1 DRIVERS 56
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58

6.2 RESTRAINTS 59
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
6.4.1 PRODUCT RECALLS 63
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63
7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64
7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69
8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71
8.1 OVERVIEW 72
8.2 VIRAL 75
8.2.1 CORONAVIRUS 76
8.2.2 INFLUENZA VIRUS 76
8.2.3 ADENOVIRUS 76
8.2.4 RHINOVIRUS 76
8.2.5 ROTAVIRUS 76
8.2.6 OTHERS 76
8.3 BACTERIAL 77
8.3.1 PNEUMONIAE 78
8.3.2 BORDETELLA PERTUSSIS 78
8.3.3 STAPHYLOCOCCUS 78
8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79

9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81
9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89
10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91
10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99
11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100
11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107
12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108
12.1 NORTH AMERICA 109
12.1.1 U.S. 116
12.1.2 CANADA 119
12.1.3 MEXICO 122
13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 125
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 125
14 SWOT ANALYSIS 126

15 COMPANY PROFILE 127
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMRIEUX SA) 127
15.1.1 COMPANY SNAPSHOT 127
15.1.2 REVENUE ANALYSIS 127
15.1.3 COMPANY SHARE ANALYSIS 128
15.1.4 PRODUCT PORTFOLIO 128
15.1.5 RECENT DEVELOPMENTS 129
15.2 F. HOFFMANN-LA ROCHE LTD 130
15.2.1 COMPANY SNAPSHOT 130
15.2.2 REVENUE ANALYSIS 130
15.2.3 COMPANY SHARE ANALYSIS 131
15.2.4 PRODUCT PORTFOLIO 131
15.2.5 RECENT DEVELOPMENT 132
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 133
15.3.1 COMPANY SNAPSHOT 133
15.3.2 RECENT FINANCIALS 133
15.3.3 COMPANY SHARE ANALYSIS 134
15.3.4 PRODUCT PORTFOLIO 134
15.3.5 RECENT DEVELOPMENT 135
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 136
15.4.1 COMPANY SNAPSHOT 136
15.4.2 RECENT FINANCIALS 136
15.4.3 COMPANY SHARE ANALYSIS 137
15.4.4 PRODUCT PORTFOLIO 137
15.4.5 RECENT DEVELOPMENTS 138
15.5 QIAGEN 139
15.5.1 COMPANY SNAPSHOT 139
15.5.2 RECENT FINANCIALS 139
15.5.3 COMPANY SHARE ANALYSIS 140
15.5.4 PRODUCT PORTFOLIO 140
15.5.5 RECENT DEVELOPMENT 140
15.6 ABBOTT 141
15.6.1 COMPANY SNAPSHOT 141
15.6.2 REVENUE ANALYSIS 141
15.6.3 PRODUCT PORTFOLIO 142
15.6.4 RECENT DEVELOPMENT 142
15.7 AKONNI BIOSYSTEMS, INC. 143
15.7.1 COMPANY SNAPSHOT 143
15.7.2 PRODUCT PORTFOLIO 143
15.7.3 RECENT DEVELOPMENT 143
15.8 APPLIED BIOCODE, INC. 144
15.8.1 COMPANY SNAPSHOT 144
15.8.2 PRODUCT PORTFOLIO 144
15.8.3 RECENT DEVELOPMENTS 145
15.9 BD 146
15.9.1 COMPANY SNAPSHOT 146
15.9.2 REVENUE ANALYSIS 146
15.9.3 PRODUCT PORTFOLIO 147
15.9.4 RECENT DEVELOPMENTS 147
15.10 BIOCARTIS 148
15.10.1 COMPANY SNAPSHOT 148
15.10.2 REVENUE ANALYSIS 148
15.10.3 PRODUCT PORTFOLIO 149
15.10.4 RECENT DEVELOPMENT 149
15.11 BIO-RAD LABORATORIES, INC. 150
15.11.1 COMPANY SNAPSHOT 150
15.11.2 REVENUE ANALYSIS 150
15.11.3 PRODUCT PORTFOLIO 151
15.11.4 RECENT DEVELOPMENT 151
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 152
15.12.1 COMPANY SNAPSHOT 152
15.12.2 REVENUE ANALYSIS 152
15.12.3 PRODUCT PORTFOLIO 153
15.12.4 RECENT DEVELOPMENT 153
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 154
15.13.1 COMPANY SNAPSHOT 154
15.13.2 RECENT FINANCIALS 154
15.13.3 PRODUCT PORTFOLIO 155
15.13.4 RECENT DEVELOPMENTS 155
15.14 HOLOGIC, INC. 156
15.14.1 COMPANY SNAPSHOT 156
15.14.2 RECENT FINANCIALS 156
15.14.3 PRODUCT PORTFOLIO 157
15.14.4 RECENT DEVELOPMENT 157
15.15 MIRXES PTE LTD. 158
15.15.1 COMPANY SNAPSHOT 158
15.15.2 PRODUCT PORTFOLIO 158
15.15.3 RECENT DEVELOPMENT 158

15.16 NANMIX, INC. 159
15.16.1 COMPANY SNAPSHOT 159
15.16.2 PRODUCT PORTFOLIO 159
15.16.3 RECENT DEVELOPMENT 159
15.17 PROMINEX INC. 160
15.17.1 COMPANY SNAPSHOT 160
15.17.2 PRODUCT PORTFOLIO 160
15.17.3 RECENT DEVELOPMENT 160
15.18 QUANTUMDX GROUP LTD. 161
15.18.1 COMPANY SNAPSHOT 161
15.18.2 PRODUCT PORTFOLIO 161
15.18.3 RECENT DEVELOPMENTS 161
15.19 SEEGENE INC. 162
15.19.1 COMPANY SNAPSHOT 162
15.19.2 REVENUE ANALYSIS 162
15.19.3 PRODUCT PORTFOLIO 163
15.19.4 RECENT DEVELOPMENTS 166
15.20 SIEMENS HEALTHCARE GMBH 167
15.20.1 COMPANY SNAPSHOT 167
15.20.2 RECENT FINANCIALS 167
15.20.3 PRODUCT PORTFOLIO 168
15.20.4 RECENT DEVELOPMENT 168
15.21 THERMOFISHER SCIENTIFIC INC. 169
15.21.1 COMPANY SNAPSHOT 169
15.21.2 RECENT FINANCIALS 169
15.21.3 PRODUCT PORTFOLIO 170
15.21.4 RECENT DEVELOPMENT 170
16 QUESTIONNAIRE 171
17 RELATED REPORTS 174

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.